The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, explains James Chalmers, MD, University of Dundee.
James Chalmers, MD
Advertisement
University of Dundee
Articles by James Chalmers, MD
Different dosages of brensocatib proved effective in treating people living with bronchiectasis when studied in the ASPEN trial.
The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the roots of the condition.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS
2
House Panel Advances Bills to Expand Veterans’ Health Care Access
3
Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplant
4
Racial Gaps in Cancer Pain Management Persist in Community Care: Ila Sruti, MPH
5